Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 3 7Phase 1/2 4Phase 4 3Phase EARLY_PHASE1 1Phase 1 1

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, Non-Hodgkin 2

Interventions

Cytarabine 34Cyclophosphamide 21Vincristine 20Methotrexate 18Dexamethasone 18Mercaptopurine 16Idarubicin 16nilotinib 15Daunorubicin 15Imatinib Mesylate 13fludarabine 12Granulocyte Colony-Stimulating Factor 12Asparaginase 12Rituximab 11Doxorubicin 10Prednisolone 9Etoposide 8Prednisone 7Thioguanine 6Teniposide 6Mitoxantrone 6Dasatinib 6venetoclax 5fludarabine phosphate 5Vindesine 5Stem Cell Transplantation 5Ifosfamide 5Azacitidine 4posaconazole 3pirtobrutinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × pirtobrutinib × Other hematologic neoplasm × Clear all
NCT07218341 2026-05-22

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Eli Lilly and Company

Phase 4 Recruiting
150 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06876649 2026-03-02

A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

Eli Lilly and Company

Phase 4 Recruiting
787 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06876662 2026-03-02

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Eli Lilly and Company

Phase 4 Recruiting
279 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡